SOURCES SOUGHT
A -- Becton Dickinson LSRFortressa High Throughput Sampler and Becton Dickinson LSRFortressa Laser Option
- Notice Date
- 7/15/2015
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC54422-91A
- Archive Date
- 8/18/2015
- Point of Contact
- Kelly L Dempsey, Phone: 3016248788
- E-Mail Address
-
kelly.dempsey@nih.gov
(kelly.dempsey@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Genome Integrity (LGI), plans to procure on a sole source basis an LSRFortressa High Throughput Sampler and a special order laser upgrade option for the LSRFortressa System from Becton Dickinson (BD) Biosciences, 2350 Qume Drive, San Jose, CA 95131. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b) (1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541712 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery shall be made within thirty (30) days after receipt of award. It has been determined there are no opportunities to acquire green products or services for this procurement. BD Biosciences High Throughput Sampler The BD High Throughput Sampler (HTS) option for the BD LSRFortessa will provide rapid, fully automated sample acquisition from microtiter plates. In high-throughput mode, the HTS can process a 96-well plate in fewer than 15 minutes. Standard throughput mode can be selected for acquisition of larger sample volumes. Even with the high acquisition speed, carryover tolerances from one well to the next are less 0.5%. Low carryover is essential in research applications to ensure sample purity and data integrity. The HTS option will support many of the research applications of NCI investigators and is compatible with 96-well U, V, and flat-bottom plates as well as 384-well microtiter plates. It is operated by the BD FACSDiva software which allows delivery protocols to be customized and used multiple times with user-defined mixing, wash, and analysis parameters. The Facility currently operates six (6) flow cytometers manufactured by BD Biosciences. BD Biosciences Laser Upgrade Option In addition, the LGI Flow Cytometry Core Facility is proposing to procure a 561nm Yellow-Green Laser Upgrade for the BD LSRFortessa flow cytometry cell analyzer to enhance the analysis capabilities of red fluorescent proteins, mCherry, dTomato and DsRed in addition to more efficient excitation of antibodies stained with phycoerythrin (PE) and PE tandems. Currently, the LSRII is the only analyzer in the facility with a 561nm laser installed and only one PMT detector is available for that laser. There has been a growing need for another flow cytometry cell analyzer in the facility with a 561nm laser with multiple PMT detectors. The Facility currently operates 6 flow cytometers manufactured by BD Biosciences. BD Biosciences is uniquely qualified for this procurement because although the laser, octagon, PMTs and optical filters are separate components, they will be installed inside the BD LSRFortessa and will become integral elements of the existing instrument. Three PMT switch boxes will be installed to allow multiple configurations utilizing the 22 parameters. The installation will involve changing the optical configuration of the instrument and this requires proprietary software changes that only BD Biosciences Field Service Engineers have the ability to perform. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11:00 AM EDST, on August 3, 2015. All responses and questions must be in writing and emailed to Kelly Dempsey, Contracting Officer via electronic mail at kelly.dempsey@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (www.sam.gov). Reference: N02RCC5442-91A on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC54422-91A/listing.html)
- Place of Performance
- Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Laboratory of Genome Integrity, 41 Medlars Drive, Bldg 41, Room A101C, Bethesda, MD 20892, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03797789-W 20150717/150715235530-a2eb86e8ca42b0aaece1bbb35bde7213 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |